IFNB1 and neoplasm: However, because the effects of the recombinant protein are locally mediated and are short-lived in vivo, and its systemic administration leads to toxicity, expression of IFN-β from a gene therapy or oncolytic virus within the tumor represents a promising means to apply this cytokine [37].